Yesterday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of Mundipharma’s pegfilgrastim biosimilar.
Yesterday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of Mundipharma’s pegfilgrastim biosimilar.
If it is authorized by the European Commission (EC), the biosimilar, which has the trade name Pegfilgrastim Mundipharma, will be authorized for sale throughout the European Union as a 6-mg solution for injection to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy.
Mundipharma, a network of independent companies that operates in 120 countries worldwide and distributes a number of biosimilars in the European Union, already has a marketed biosimilar pegfilgrastim, Pelmeg, which it acquired along with biosimilar developer Cinfa Biotech in 2018.
In November 2018, the EC granted a marketing authorization for that product for the same indication and same dose as the product for which the decision was rendered yesterday. Pelmeg gained its own positive recommendation from CHMP on the basis of a comprehensive package of data including a comparability study of pharmacodynamics and immunogenicity that was presented at the American Society of Hematology’s annual meeting in December 2017.
Since Pelmeg's authorization, Mundipharma has launched the biosimilar product in a range of markets, including Germany, the Netherlands, Ireland, and the United Kingdom, and has struck a deal with Budapest-based Egis Pharmaceuticals to distribute the product in Hungary, Romania, Lithuania, and Latvia.
The fact that Mundipharma already sells Pelmeg in the European context raises questions as to how the Pegfilgrastim Mundipharma product may fit in with the company's business strategy, although one possibility is that the product could be a separate brand name for the same biosimilar. In the European Union, duplicate marketing authorization applications are permitted on a case-by-case basis to help facilitate comarketing or for reasons concerning the public health.
Such duplicate authorizations are not uncommon for biosimilars; for example, earlier in 2019, the European Commission authorized Fresenius Kabi’s adalimumab biosimilar as both Kromeya and Idacio, and the 2 brands carry different indications.
Mundipharma did not respond to inquiries from The Center for Biosimilars® to clarify whether Pegfilgrastim Mundipharma is a separately developed product or a duplicate of Pelmeg.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.